The Oklahoma Medical Research Foundation's ten-year COBRE, """"""""Science in a Culture of Mentoring (RR15577) has been transformative in providing the foundation for growth in Immunology research in our state. This COBRE provided mentoring and support to launch 12 independent research careers and the infrastructure has led to 10 """"""""non NCRR NIH institutes"""""""" program or center grants as a direct result of this funding. OMRF and Oklahoma can now legitimately claim to be a """"""""Center"""""""" for Immunology in the United States. Now, 16 COBRE eligible investigators present projects to be supported by mentoring and critical Core support. We have found that Mentoring and Core support is fundamental to our success. The Human Monoclonal Antibody (hmAb) Core grows out of COBRE supported scientific observations {Nature 2008), which allow rapid production of hmAbs after vaccination. With over 300 hmAbs already produced and many projects waiting, this Core is poised to provide unique research tools that should allow our COBRE Investigators to make major advances. The Serum Analyte and Biomarker Core expands on OMRF's strengths in human autoantibody detection, cytokine/chemokine measurements, epitope mapping and serum analyte development. It will provide access to the centralized generation of quality controlled data to assist projects in autoimmunity, gene-environment interactions, and human immune responses. The Immunophenotyping Core applies new whole blood multiparameter testing of detailed subsets of B cells, T cells, and other cell types. This Core provides centralized SOPs, tested reagents and experimental designs for complex human disease questions in many immunology-based projects. Finally, the Clinical Core provides patient/control identification, recruitment, phenotype characterization and human subjects training to COBRE investigators, with all 17 proposed pilot projects requesting use of this Core. The Pilot Project Core will identify, support and mentor COBRE eligible junior scientists through one-year pilot projects. Extremely productive in prior years, 17 applications were received for this cycle. We view these pilot funds as fundamental to our plans for the future of our Immunology focus in Oklahoma. The Administrative Core will provide mentoring teams and administrative support to 16 COBRE eligible junior scientists, implement and expand multidisciplinary enrichment programs, support collaborations between Oklahoma investigators, evaluate and manage the effectiveness of pilot projects. We are confident that with these additional funds OMRF and Oklahoma can have an outstanding Center of Immunology Excellence.

Public Health Relevance

This OMRF COBRE has led to an explosive expansion in Immunology based, clinically relevant research in Oklahoma. Through outside recruits and development of local junior scientists, this funding mechanism has resulted In exciting new discoveries in vaccine immunology, autoimmunity, Alzheimers'research and other complex human diseases. Transition of this productive COBRE to a Cores Center will help launch additional new investigative careers and facilitate additional Program support, from a variety of other national agencies.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Center Core Grants (P30)
Project #
5P30GM103510-05
Application #
8722573
Study Section
Special Emphasis Panel (ZRR1-RI-2 (01))
Program Officer
Douthard, Regine
Project Start
2010-09-01
Project End
2015-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
5
Fiscal Year
2014
Total Cost
$1,223,569
Indirect Cost
$495,254
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Koelsch, Kristi A; Cavett, Joshua; Smith, Kenneth et al. (2018) Evidence of Alternative Modes of B Cell Activation Involving Acquired Fab Regions of N-Glycosylation in Antibody-Secreting Cells Infiltrating the Labial Salivary Glands of Patients With Sjögren's Syndrome. Arthritis Rheumatol 70:1102-1113
Hinks, Anne; Marion, Miranda C; Cobb, Joanna et al. (2018) Brief Report: The Genetic Profile of Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis. Arthritis Rheumatol 70:957-962
Patel, Zubin; Lu, Xiaoming; Miller, Daniel et al. (2018) A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. Hum Mol Genet :
Kheir, Joseph M; Guthridge, Carla J; Johnston, Jonathon R et al. (2018) Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med 5:e000247
Young, K A; Munroe, M E; Harley, J B et al. (2018) Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus. Lupus 27:1524-1531
Hanscombe, Ken B; Morris, David L; Noble, Janelle A et al. (2018) Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Hum Mol Genet 27:3813-3824
Bagavant, Harini; Dunkleberger, Micah L; Wolska, Nina et al. (2018) Antibodies to periodontogenic bacteria are associated with higher disease activity in lupus patients. Clin Exp Rheumatol :
Langefeld, Carl D; Ainsworth, Hannah C; Cunninghame Graham, Deborah S et al. (2017) Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun 8:16021
Aberle, Teresa; Bourn, Rebecka L; Chen, Hua et al. (2017) Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus. Lupus Sci Med 4:e000176
Munroe, Melissa E; Young, Kendra A; Kamen, Diane L et al. (2017) Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features. Arthritis Rheumatol 69:630-642

Showing the most recent 10 out of 125 publications